NASDAQ$YMAB
Y-mAbs Therapeutics Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Y-mAbs reported third quarter results with a focus on DANYELZA commercial business and SADA PRIT platform development.
Y-mAbs reported total net revenues of $18.5 million for Q3 2024, a 10% decrease compared to Q3 2023. The company continues to focus on DANYELZA commercial business and SADA PRIT platform development.
- Total DANYELZA net product revenues were $18.5 million for Q3 2024.
- Entered into an exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan, recognizing an upfront payment of $2.0 million in Q4 2024.
- Extension of primary DANYELZA U.S. patent through February 2034 was achieved.
- Continued geographic expansion of DANYELZA with new market revenues recorded in the third quarter from Turkey.
Headline financials
Revenue & EPS history
Y-mAbs · Revenue · Quarterly
$18.5M
Forward guidance
Management reiterates its full year 2024 guidance.
Tailwinds
- Anticipated Total Net Revenues expected to be between $87 million and $95 million.
- Anticipated Operating Expenses expected to remain between $115 million and $120 million.
- Anticipated Total Annual Cash Investment expected to remain between $15 million and $20 million.
- Cash and Cash Equivalents anticipated to continue to support operations as currently planned into 2027.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 5 quarterly earnings reports · overlaid with Q3 2024
+2.2%
Avg return
Earnings day
-4.2%
Avg return
5 days after
-5.4%
Avg return
30 days after
36%
10 / 28 earnings
Positive
+54.6%
Q4 2022
Best reaction
-21.1%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | — | — | — | |
| Q2 2025 | +0.0% | +0.0% | +0.8% | |
| Q1 2025 | -11.4% | +0.2% | +14.0% | |
| Q4 2024 | -4.4% | -0.4% | -9.9% | |
| Q3 2024 | -4.4% | -15.2% | -32.3% | |
| Q2 2024 | -3.5% | +9.4% | +18.4% | |
| Q1 2024 | -21.1% | -25.4% | -28.7% | |
| Q4 2023 | +14.5% | +2.0% | -0.2% | |
| Q3 2023 | +6.1% | — | — | |
| Q2 2023 | -5.0% | — | — | |
| Q1 2023 | +33.6% | — | — | |
| Q4 2022 | +54.6% | — | — | |
| Q3 2022 | +15.4% | — | — | |
| Q2 2022 | -5.6% | — | — | |
| Q1 2022 | +13.2% | — | — | |
| Q4 2021 | +12.9% | — | — | |
| Q3 2021 | -19.7% | — | — | |
| Q2 2021 | -17.8% | — | — | |
| Q1 2021 | +20.8% | — | — | |
| Q4 2020 | -3.6% | — | — | |
| Q3 2020 | -3.0% | — | — | |
| Q2 2020 | -1.6% | — | — | |
| Q1 2020 | +14.4% | — | — | |
| Q4 2019 | -8.7% | — | — | |
| Q3 2019 | -1.6% | — | — | |
| Q2 2019 | +2.4% | — | — | |
| Q1 2019 | -9.9% | — | — | |
| Q4 2018 | -4.4% | — | — | |
| Q3 2018 | -1.1% | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro